You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2025

Details for New Drug Application (NDA): 217813

✉ Email this page to a colleague

« Back to Dashboard

NDA 217813 describes DEFLAZACORT, which is a drug marketed by Tris Pharma Inc, Upsher Smith Labs, Zydus Lifesciences, Aurobindo Pharma Ltd, and Sun Pharm, and is included in six NDAs. It is available from six suppliers. Additional details are available on the DEFLAZACORT profile page.

The generic ingredient in DEFLAZACORT is deflazacort. There are three drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the deflazacort profile page.

Summary for 217813

Tradename:	DEFLAZACORT
Applicant:	Tris Pharma Inc
Ingredient:	deflazacort
Patents:	0

Pharmacology for NDA: 217813

Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Suppliers and Packaging for NDA: 217813

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
DEFLAZACORT	deflazacort	SUSPENSION;ORAL	217813	ANDA	Cranbury Pharmaceuticals, LLC	27808-249	27808-249-01	13 mL in 1 BOTTLE (27808-249-01)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SUSPENSION;ORAL			Strength	22.75MG/ML
Approval Date:	Apr 25, 2024	TE:	AB	RLD:	No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.